Research
HC Wainwright Initiates Immuneering at Buy With $14 Price Target
Immuneering (IMRX) has an average rating of buy and mean price target of $18.17, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)
$IMRX
